High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients
Open Access
- 27 June 2011
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 73 (1), 106-114
- https://doi.org/10.1111/j.1365-2125.2011.04054.x
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • High dose methotrexate (HD MTX) is generally well tolerated, although unpredictable acute toxicities occur frequently. • Low overall toxicity in paediatric patients and increased liver toxicity in adults has been reported, but there are no reports addressing the relationship between acute liver toxicity and gender in patients treated with HD MTX. • Previous studies in animals suggested involvement of the 7-hydroxy-methotrexate metabolite in acute liver toxicity, but this has not been investigated in humans and the aetiology of acute liver toxicity remains unclear. WHAT THIS STUDY ADDS • Survival has increased dramatically over the past decades for patients with malignancies such as osteosarcoma and since these patients are frequently children or adolescents at the time of high dose methotrexate, identification of risk factors for toxicity increases the possibility for tailoring treatment. • Our study presents a detailed analysis of acute toxicity, folate concentrations and pharmacokinetics of both methotrexate and its major extracellular metabolite 7-hydroxy-methotrexate and identifies several factors that are highly correlated with acute liver toxicity. AIMS To investigate the relationships between pretreatment folate concentrations, MTX pharmacokinetics and acute toxicities following high dose methotrexate (HD MTX) therapy. METHODS MTX and its major extracellular metabolite 7-OH-MTX were measured in eight serum samples per HD MTX cycle in 65 consecutive osteosarcoma patients (288 cycles) and AUC (area under the blood concentration–time curve) was calculated. Pretreatment concentrations of folate in serum (S) and erythrocytes (ER) were determined. Hepatic, renal and haematological toxicities, assessed by routine laboratory parameters, as well as mucositis were graded according to National Cancer Institute Common Terminology Criteria for adverse events (CTCAE v.3.0). Dermatitis and pleuritis were reported as occurred or not. RESULTS S- and ER-folate pretreatment concentrations increased significantly with increasing number of HD MTX cycles (P < 0.001). ER-folate pretreatment concentrations were higher among males (median 610 nmol l−1, 95% CI 550, 680) compared with females (median 465 nmol l−1, 95% CI 430, 520, P < 0.001), but showed no correlation with MTX or 7-OH-MTX pharmacokinetics. We found correlations between alanine aminotransferase peak concentration (ALATmax) and clearance of MTX (P < 0.001), gender (P < 0.001), age (P < 0.001) and 7-OH-MTX concentrations (P < 0.001), the latter being the main factor influencing ALATmax. CONCLUSION Our results suggest that 7-OH-MTX is involved in the development of HD MTX hepatic toxicity and that young female patients are most affected.Keywords
This publication has 34 references indexed in Scilit:
- Effectiveness and Toxicity of Methotrexate in Juvenile Idiopathic Arthritis: Comparison of 2 Initial Dosing RegimensThe Journal of Rheumatology, 2010
- Understanding and Managing Methotrexate NephrotoxicityThe Oncologist, 2006
- Pretreatment Plasma Folate Modulates the Pharmacodynamic Effect of High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: “Folate Overrescue” Concept RevisitedClinical Chemistry, 2006
- Pharmacogenetics of folate-related drug targets in cancer treatmentPharmacogenomics, 2005
- Severe Encephalopathy Induced by the First but Not the Second Course of High-Dose Methotrexate Mirrored by Plasma Homocysteine Elevations and Preceded by Extreme Differences in Pretreatment Plasma FolateOncology, 2005
- Evidence for two phenotypes in the metabolism of methotrexate to 7‐hydroxymethotrexate in patients with rheumatoid arthritisArthritis & Rheumatism, 2005
- High‐dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcomaCancer, 2004
- Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological respondersEuropean Journal of Cancer, 2003
- The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapyCancer Letters, 1980
- Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate ToxicityNew England Journal of Medicine, 1977